Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.
Petrylak D, Kantoff P, Rotshteyn Y, Israel R, Olson W, Ramakrishna T, Morris S. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer. Journal Of Clinical Oncology 2011, 29: 158-158. DOI: 10.1200/jco.2011.29.7_suppl.158.Peer-Reviewed Original ResearchMonomethyl auristatin EFree MMAEProstate cancer cellsProstate cancerRefractory metastatic prostate cancerDose-proportional PKTaxane-containing regimenCommon laboratory abnormalitiesDose-proportional mannerPhase I trialCancer cellsClinical disease progressionMetastatic prostate cancerOngoing phase IEnzyme-linked immunosorbent assay (ELISA) methodPotential clinical utilityImmunosorbent assay (ELISA) methodECOG statusAdverse eventsEscalation studyLaboratory abnormalitiesI trialThird dosesAntibody therapyLiquid chromatography/mass spectrometry/mass spectrometry method